Introduction: Biologic agents targeting interleukin-6 (IL-6) have gained attention as a promising treatment option for non-infectious uveitis (NIU) cases resistant to first-line therapies. IL-6 plays a pivotal role in the pathogenesis of uveitic conditions and its complications (i.e. macular edema and neovscularization). This review aims to assess the therapeutic potential of IL-6 inhibitors in managing NIU, especially focused in clinical outcomes, such as visual acuity and macular edema. Methods: Narrative review of studies evaluating the efficacy of IL-6 inhibitors in patients with NIU. Parameters assessed include control of inflammation, corticosteroid-sparing effects, visual acuity improvement, and reduction of macular edema. Results: IL-6 inhibitors have demonstrated efficacy in controlling inflammation in 34percent-flag-change to 88percent-flag-change of cases and reducing corticosteroid dependence in approximately 55percent-flag-change of patients. Complete remission rates have been reported between 60percent-flag-change and 70percent-flag-change, with improvement in macular edema observed in 35.8percent-flag-change to 100percent-flag-change of cases. These results suggest that IL-6 inhibitors could be a therapeutic alternative for managing difficult cases of NIU. Conclusions: IL-6 inhibitors, including Tocilizumab and Sarilumab, have shown efficacy in controlling inflammation, improving visual outcomes, and reducing corticosteroid dependence in NIU. However, despite these promising results, further studies are needed to establish their long-term efficacy and safety. These therapies hold great potential for the future management of patients with uveitis.
